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Abstract
Rationale, aims and objectives Differences in the performance of medical care may be
due to variation in the introduction and diffusion of medical innovations. The objective of
this paper is to compare seven European countries (United Kingdom, the Netherlands, West
Germany, France, Spain, Estonia and Sweden) with regard to the year of introduction of six
specific pharmaceutical innovations (antiretroviral drugs, cimetidine, tamoxifen, cisplatin,
oxalaplatin and cyclosporin) that may have had important population health impacts.
Methods We collected information on introduction and further diffusion of drugs using
searches in the national and international literature, and questionnaires to national inform-
ants. We combined various sources of information, both official years of registration
and other indicators of introduction (clinical trials, guidelines, evaluation reports, sales
statistics).
Results and conclusions The total length of the period between first and last introduction
varied between 8 years for antiretroviral drugs and 22 years for cisplatin. Introduction in
Estonia was generally delayed until the 1990s. The average time lags were smallest in
France (2.2 years), United Kingdom (2.8 years) and the Netherlands (3.5 years). Similar
rank orders were seen for year of registration suggesting that introduction lags are not only
explained by differences in the process of registration. We discuss possible reasons for
these between-country differences and implications for the evaluation of medical care.
Introduction
The introduction and diffusion of
innovative drugs
Key goals of health systems are to improve the health of the
population and to do so in an equitable way [1]. Although the
health of the population to a large extent is influenced by broader
improvements in living conditions [2], well-functioning health
care systems also contribute to the health of populations. However,
their ability to do so varies and there is increasing interest in
measuring their performance; the introduction and diffusion of
medical innovations should be an important part of this process.
There have long been concerns about the delay in introducing
innovative drugs in different countries [3,4]. These have drawn on
analyses of variations in the year of registration between countries.
For instance, this has been reported to have been somewhat
delayed in the United States, Sweden and Italy when compared
with United Kingdom, West Germany and France [3,4]. However,
given the relative ease in obtaining data on year of registration,
delays in the registration process have been the main focus of
debate about international variation in the timing of introduction of
innovative drugs [5,6] even though other health system factors
have also been identified [7,8].
In the European Union (EU), there has been a process of har-
monizing the regulation of new drugs [9]. However, for a drug to
impact on the health of the population, it must also be used in
clinical practice. This will often not coincide with registration
decisions. For instance, pharmaceuticals may have been used
in clinical trials before registration year (which may have a
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considerable impact if trials are relatively large and the condition
is rare), or there may have been a delay after the registration year
before the drug is widely adopted.
The theory of diffusion [10] of innovations envisages cumula-
tive adoption following an S-shaped curve, with Rogers describing
diffusion of innovations as ‘the process through which an innova-
tion is communicated through certain channels over time among
the members of a social system’ [11]. The adaptors of the innova-
tion are classified into five different categories. (1) Innovators,
about 2.5% of the ‘population’. They are not opinion leaders, but
prone to novelty and with little to lose. (2) Early adopters include
opinion leaders that interact with innovators and like-minded
persons. Thereafter come: (3) early majority, who tend to rely
heavily on the early adopters and (4) the late majority, which relies
in turn on the early majority. They are considered more conserva-
tive and will not adopt an innovation until it is standard practice.
Finally, (5) the ‘laggards’, (or traditionalists), wedded to the ‘old
ways’, are critical of new ideas and will only accept them once the
new idea has become mainstream or even tradition.
There are several published empirical studies on diffusion of
innovation. Commonly, these are descriptive studies showing the
variation in the time of introduction of new innovations. Other
studies analyse factors that could explain the process of diffusion.
Furthermore, there has been concerns about inequity in medical
care related to variations in the diffusion of innovation to different
population groups such as racial and ethnic disparities [12–15] as
well as gender, age and social differences [16,17]. Most studies
analyse diffusion within a specified country but some make inter-
national comparisons [18–21]. These studies have used a variety of
empirical data such as health administrative data [14,22], medical
records or questionnaires to or interviews with key informants
[23–25]. For pharmaceuticals, official data on registration as well
as sales and prescribing statistics of pharmaceuticals [19,20,26]
have been used.
Applying the theory of diffusion to the introduction of new
pharmaceuticals implies the need to obtain empirical data showing
when the innovators and early adaptors started to use the new
treatment. However, where our goal is to identify when an inno-
vation might be expected to improve the health of the population,
we will need data also on the diffusion of the innovation.
Development of indicators of the effectiveness
of health systems
This study is part of the Amiehs project (Avoidable mortality in
the European Union: Towards better indicators for the effective-
ness of health systems) [27], which seeks to develop indicators of
the effectiveness of health systems. Mortality for specific causes
of death that are considered amenable to medical care is increas-
ingly used as an indicator of the quality of health care [28]. High
death rates from these causes, collectively termed avoidable or
amenable mortality, have been suggested to motivate further
investigations of the quality of health care. There is now extensive
experience in their use in different countries, health administrative
areas, socioeconomic and ethnic groups and with respect to
gender [29,30].
Several studies have shown that mortality from these causes
have decreased more rapidly than total mortality in several indus-
trialized countries [30–32]. For some avoidable causes of death,
mortality has also been found to decline faster after the introduc-
tion of innovations in health care, such as improved management
of hypertension, leading to lower mortality from cerebrovascular
disease and screening to prevent deaths from cervical cancer [33].
However, to assess the effectiveness of health care at a population
level, a precise measure of the timing of the introduction of inno-
vations is necessary in order to evaluate whether they have
impacted on the health of the population.
The objective of this paper is to analyse the variation in the
introduction of specific pharmaceutical innovations that may influ-
ence the mortality outcome among seven European countries – for
comparison – applying both official registration data and indica-
tors of the start of the diffusion of the innovative drugs.
Material and methods
Six pharmaceutical innovations were included in the study
(Table 1). These were selected on the basis of their effectiveness,
as demonstrated in clinical trials, in reducing specific causes of
death, where those causes were sufficiently common and where
there had been an observed decline in mortality in recent decades,
making it possible to undertake robust statistical testing for any
association in another part of the project.
Cisplatin was introduced for the treatment of testicular cancer
already in the 1970s and has been shown to improve outcome
when included in combination therapy [34]. The H2-receptor
antagonist cimetidine was evaluated in clinical trials of peptic
ulcer treatment in the late 1970s supporting evidence on the ulcer
healing [35,36]. Tamoxifen has been shown to reduce recurrences
and mortality from breast cancer in several clinical trials [37].
Cyclosporin is an effective immunosuppressant used in renal
transplantation [38]. Clinical trials have found oxalaplatin to be
effective as a component of combination therapy for advanced
colorectal cancer [39,40]. The antiretroviral drugs azidothymidine
and zidovudine were shown to improve survival with AIDS in
randomized clinical trials [41]
For these specific innovations, a questionnaire was developed
and answered by the participating partners from the United
Kingdom, the Netherlands, Germany (West Germany), France,
Spain, Estonia and Sweden. The partners collected data from offi-
cial sources and from key informants. Information was sought on
the first introduction of the innovation and the period of imple-
mentation. For the first part, documents on the official and organ-
ized introduction were asked for. These were for instance, the
registration year for pharmaceuticals as well as the year of national
Table 1 Interventions included in the analysis of timing of innovations
Target disease Medical innovation
Testicular cancer Treatment with cisplatin
Peptic ulcer Treatment with cimetidine
Breast cancer Treatment with tamoxifen
Acute nephritis
and nephrosis
Immunosuppressive treatment with
cyklosporin for kidney transplantation
Colorectal cancer Treatment with oxalaplatin
HIV Treatment with antiretroviral drugs
(azidothymidine or zidovudine)
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programs and guidelines. To get information on the implementa-
tion of the interventions, data on scientific or committee reports
evaluating the implementation were requested. For pharmaceuti-
cals, sales statistics were collected, if available. This data was used
to verify that the medicine has been available in the respective
country and also to indicate the speed of the implementation. To
facilitate comparisons between countries, statistics on daily
defined doses (DDD) [42] were asked for.
Sales statistics were available from Sweden (1977–2008; only
from year of registration), Estonia (1999–2008), Germany (1999–
2008; hospital prescribing and privately insured patients were
unavailable)) France (2002–2007), United Kingdom (mainly
1999; hospital prescribing unavailable) and Spain (2000–2008;
hospital prescribing unavailable). The measure used differed
between countries and pharmaceuticals. Sales statistics measured
by DDD was available for most of the period from Sweden,
Estonia and Germany only.
In addition, a literature review was performed for each innova-
tion and country. Articles registered in Medline with any of the key
words (or words in title or abstract) ‘standards, guidelines, official
policy, consensus development, evaluation studies or clinical trial’
in combination with the terms for the innovation and the country
names were scrutinized for applicable information. The country
representatives were asked to comment on the data found and to
collect further data based on the information.
The data from the questionnaire and literature review were
combined in order to get several indicators of the diffusion process
of the specific innovations in each country. We looked for both
very early indicators of early adaptors introducing the method and
indicators of a continued diffusion of the method and used specific
criteria for defining the start of the diffusion:
Criteria 1: The first documented year of introduction of the
pharmaceutical in a specific country was used to define the year of
the start of diffusion. The start of first clinical trials or clinical
studies, available sales statistics from the introduction period or
evaluation reports describing the introduction of the pharmaceuti-
cals were accepted as data on the start of the diffusion. If the
starting year of the clinical trial was not mentioned, we used
the year 3 years before the publication year as the indicator of the
introduction. When no data was available, the year of registration
was used.
Criteria 2: In order to define the start of the diffusion, we also
judged that data indicating a continued diffusion of the drug was
needed. This was indicated by further clinical trials, evaluation
reports, guidelines and sales statistics.
Thus, several data was used for each statement of the year of
introduction. We present in this article the references to the early
indicators of the start of diffusion and to evaluation reports and
guidelines indicating the further diffusion of the pharmaceuticals.
The availability of sales statistics was presented above. When data
was available, we analysed the year when the peak level of sales of
the pharmaceutical occurred and the diffusion time from start of
diffusion to this year. Further references are available in the
Amiehs report [27] on the Internet.
The variation in year of introduction among the countries was
studied using both official data of year of registration and data on
the start of the diffusion of the pharmaceuticals, respectively. The
time lag between the first introduction in any of the countries
and in the others was calculated. A mean score of the time lag
including data on all the six pharmaceuticals was analysed for
each country.
Results
With the exception of Estonia, cisplatin was introduced for the
treatment of testicular cancer in all countries in the 1970s or early
1980s (Table 2). In Estonia, it was delayed until the 1990s, when
the country had achieved independence. In most countries, the
introduction started with clinical trials or other clinical studies in
the period 1976–1981 [43–47], while registration was some years
later, that is, between 1979 and 1983. In several countries, cisplatin
was registered for the treatment of cancers at several other sites so
sales data could not be used to evaluate its diffusion as a treatment
for testicular cancer. One study from the Netherlands found that
cisplatin was not in widespread use between 1970 and 1978 [48]
(Table 3). In the United Kingdom, The UK Children’s Cancer
Study Group [49,50] followed up children with testicular cancer
from 1979 to 1988, during which period only about 7 % of patients
received the drug.
Cimetidine was introduced for the treatment of peptic ulcer
in most countries in the late 1970s or early 1980s. In Estonia
however, the drug was first registered in 1993. In Germany [51]
and France [52,53], clinical trials started a few years before the
year of registration. In Spain, the year of registration and first
clinical trial coincided [54]
Tamoxifen, used to treat breast cancer, was introduced in most
countries in the late 1970s or early 1980s. However, in Estonia, it
was first available in the 1990s, where it was registered in 1992. In
Germany, clinical trials [12] were reported a few years before
registration, and in Sweden, the first reported clinical trials [55,56]
coincided with registration.
Immunosuppressive treatment with cyclosporine following
kidney transplantation was introduced in the 1980s in most coun-
tries with the exception of Estonia where it was again delayed until
the 1990s. In most countries, the year of registration and the start
of the clinical trials were close in time. However, In Germany,
clinical trials were reported 11 years before the official registra-
tion. Clinical trials were reported from United Kingdom [57,58],
the Netherlands [58], Germany [57], Spain [59] and Sweden [60].
As with cisplatin, interpretation of sales data was complicated by
its other indications.
Clinical trials of oxalaplatin started before registration (which
was usually at the end of the 1990s) in several countries. The time
lag varied between 4 years in the United Kingdom [61] and Spain
[62] to 8 years in France [63]. In some countries, the diffusion
process can be assessed by consensus statements and guidelines.
In the United Kingdom, guidelines were published in 2002, 7 years
after the introduction [64] Oxalaplatin was recommended for
patients with inoperable liver metastases to make them eligible for
surgery [65]. In Germany, a 2000 consensus statement on treat-
ment of colon cancer [66] mentioned oxalaplatin as a promising
new drug but not yet generally recommended. In Sweden [67],
oxalaplatin was recommended as one alternative in an evidence
review from 2001, that is, 13 years after the introduction [68].
The antiretroviral drugs azidothymine or zidovudine were intro-
duced in most countries between 1987 and 1995. In the Nether-
lands, the registration year coincided with the first reported clinical
trial starting in 1987 [69]. In the United Kingdom [70,71],
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Germany [72], France [73], Spain [74] and Sweden [75], clinical
trials started a few years after the year of registration. The con-
tinued implementation of treatment was verified by sales statistics
in all countries. Their use was endorsed by clinical guidelines or
recommendations in United Kingdom [76], Germany [2], Spain
[77] and Sweden [6]. The guidelines were published between 7
and 17 years after the introduction in the respective country.
As illustrated in Table 4, the variation among countries in the
introduction of new drugs was largest for cisplatin, cimetidine and
tamoxifen, all introduced first in the 1970s. For the most recent
pharmaceuticals, the antiretroviral drugs and oxalaplatin, the vari-
ation was considerably less. Some countries were consistently
among the first to introduce new drugs, such as Germany, France,
Sweden, United Kingdom and the Netherlands. Introduction of
modern drugs was delayed until after independence in Estonia,
while Spain often introduced the drugs studied later than other
countries.
The delay since the first introduction was shortest for France,
the Netherlands and United Kingdom (Table 5), and longest for
Estonia. This was true both when the official year of registration
and when other data on the start of the diffusion of innovation were
used. When the start of diffusion was used the variation was
greater and the ranking between the countries differed somewhat
from what was found using the registration year. For instance, the
delay in registration was shortest in the Netherlands (1.3 years)
while the time lag until the start of diffusion was shortest in France
(2.2 years).
For several innovations, the length of period of diffusion from
introduction to the year when the peak level of use was reached
was similar (Table 6). This was the case for treatment with cime-
tidine, oxalaplatin and cyclosporine. For some pharmaceuticals –
cisplatin, cimetidine and cyclosporine – a delay in peak level was
found in Estonia although when the time length for diffusion was
similar. In these cases, the pharmaceuticals were also introduced
later in Estonia. Also for tamoxifen, the diffusion started later in
Estonia, but this seems however to have been compensated by
a faster diffusion (11 years compared with about 20 years in
the compared countries). For treatment with cisplatin, the early
introduction in Sweden was followed by a fast diffusion, which
increased the variation among the countries further. For
zidovudine, the diffusion seems to have been fast since the sales
of the pharmaceutical peaked before or at the start of the period
of available sales statistics in most countries, that is, around the
late 1990s.
Discussion
Between-country variation in introduction
of pharmaceuticals
Several pharmaceuticals developed in the 1970s and 1980s were
introduced about the same time in most countries with the excep-
tion for Estonia, where cimetidine, cisplatin and cyclosporine were
only introduced in the 1990s. This was true also for treatment of
breast cancer with Tamoxifen, although the variation was fairly
large also among the other countries. For the drugs developed later,
oxalaplatin and antiretroviral drugs, however, introduction was at
about the same time in all countries, in the late 1980s or early
1990s.Ta
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Table 3 Guidelines and evaluation reports
indicating the continued diffusion of medical
innovations
Innovation Country Documentation Year
Treatment of testicular cancer with
cisplatin
United Kingdom Evaluation report 1989 [49]
The Netherlands Evaluation report 1991 [88]
Treatment of peptic ulcer with cimetidine The Netherlands Evaluation report 1983 [89]
Treatment of breast cancer with tamoxifen
Treatment of colorectal cancer with
oxaliplatin
United Kingdom Guidelines 2002 [64]
Germany Guidelines 2000 [66]
Sweden Guidelines 2001 [68]
Immunosuppressive treatment with
cyclosporine for kidney transplantation
of patients with acute nephritis and
nephritis
United Kingdom Evaluation report 1990 [90]
The Netherlands Evaluation report 1987 [91]
France Evaluation report 1987 [92]
Spain Evaluation report 1986 [93]
Sweden Evaluation report 1991 [94]
Treatment of HIV with the antiretroviral
drugs (azidothymidine or zidovudine)
United Kingdom Guidelines 1997 [76]
Germany Guidelines 2004 [95]
Spain Guidelines 2000 [77]
Sweden Guidelines 2005 [96]
Sweden Evaluation report 1999 [97]
Table 4 Variation in the start of diffusion of medical innovations among countries based on country-specific year of introduction
Diffusion
year Cisplatin Cimetidine Tamoxifen Cyklosporin Oxalaplatin Antiretroviral
0 Germany 1973 France 1976 Sweden, UK 1976 Germany, UK 1980 France 1988 The Netherlands 1987
1 Spain, the
Netherlands 1977
Sweden, Germany
1988
2 Sweden 1978 France 1982 France, UK 1989
3 The Netherlands,
UK 1976
Germany 1979 Sweden, the
Netherlands 1983
4 France 1977
5 UK 1981 The Netherlands,
France, Germany
1981
Spain 1985
6 Spain 1994 Spain 1993
7 UK 1995
8 Sweden, Spain
1981
Estonia 1995
9
10
11 The Netherlands,
Sweden, Estonia
1999
12 Spain 1988
13 Estonia 1993 Germany 2001
14
15
16 Estonia 1992
17 Estonia 1993
18
19
20
21
22 Estonia 1995
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These results are consistent with the aspiration by the European
countries to harmonize regulations with regards to medicines and
other pharmaceutical products. The concept of the establishment
of the Multi State Licensing Procedure in 1975 was that pharma-
ceuticals that had been approved in one member country should be
authorized in other countries. This procedure, which was not very
successful at first, was replaced in 1987 by the Concertation Pro-
cedure, which in turn was replaced in 1995 by the European
Medicines Evaluation Agency [78].
Estonia is an obvious outlier, reflecting its isolation from
international commerce before 1991. Once Estonia regained its
independence, it became integrated with the global economy,
especially since acceding to the EU in 2004, and has seen sus-
tained improvements in health care [79,80].
In general, innovative drugs were first introduced in the Neth-
erlands, the United Kingdom and in France, whether assessed by
date of registration or other indicators of when diffusion started.
The process was generally delayed in Spain, especially when
indicators of when diffusion started were considered. The delay
in Sweden was somewhat larger when assessed by the start of
diffusion than registration. Importantly, these findings demon-
strate that registration does not always coincide with uptake
of drugs, even though most attention so far has been on the
former [5,6]. Thus, it is necessary to look at other characteristics
of the health system to explain why some European citizens
wait longer to receive innovative treatments than others [7,8],
especially given the success of harmonization of the registration
process [9].
Of the more recently introduced pharmaceuticals; oxalaplatin
was first approved in France in 1996, and approved throughout the
EU through the Mutual Recognition Procedure in 1999, France
being the Reference Member State. Zidovudine was first approved
in 1987 using national licenses, before the Concertation Procedure
became mandatory for HIV/AIDS treatments. For these pharma-
ceuticals, the variation in timing in introduction was low among
the countries, including Estonia.
Table 5 The sum* and mean scores of time lag in year of introduction after the corresponding year of introduction in the first of the countries for
the six studied pharmaceuticals
Country
Sum scores DOI-data†
(years)
Mean score
DOI-data† (years)
Sum scores registration
data (years)
Mean score registration
data (years)
United Kingdom 17 2.8 9 1.5
The Netherlands 21 3.5 8 1.3
Germany 22 3.7 27 4.5
France 13 2.2 n.a. 1.5‡
Spain 38 6.3 12 2
Estonia 87 14.5 72 12
Sweden 25 4.2 13 2.2
*Sum score, total lag compared with first country, six pharmaceuticals.
†Indications of start of diffusion of innovation.
‡Based on data for four pharmaceuticals.
n.a., not applicable.
Table 6 The diffusion period* of selected medical innovations
Innovation Country
Start of
diffusion (year)
Half of peak
level (year)
Peak level
(year)
Diffusion period
(number of years)
Treatment of testicular cancer with cisplatin Germany 1973 n.d. 2001 28
Estonia 1995 2000 2005 10
Sweden 1981 n.d. 1984 3
Treatment of peptic
ulcer with cimetidine
Estonia 1993 n.d. 2000 7
Sweden 1978 1982 1986 8
Treatment of breast cancer with tamoxifen The Netherlands 1981 n.d. 2002 21
Germany 1981 n.d. 2002 20
Estonia 1992 n.d. 2003 11
Sweden 1976 1984 1996 20
Treatment of colorectal cancer with oxaliplatin Estonia 1999 2008 9
Sweden 1999 2004 2008 9
Immunosuppressive treatment with
cyclosporine for kidney transplantation
The Netherlands 1983 1998 1999 16
Estonia 1993 2001 2008 15
Sweden 1983 1991 1999 16
Treatment of HIV with zidovudine) Sweden 1988 1993 1997 9
*Period between the year of the first indication of the start of diffusion (as presented in Table 2) and the year of the peak of sales level of the
pharmaceutical in each country.
n.d., not detected during the data period available.
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For tamoxifen, there was a time lag in several countries between
the registration of the drug and its use in clinical trials. At that
time, several therapeutical strategies were being discussed and its
role of Tamoxifen seems not to have been clearly defined. Scien-
tific papers at that time argue that it had a limited role [81] and
called for more clinical trials [82], which started in most of the
countries in this study in the late 1970s and 1980s.
To define the start of the diffusion process, one needs empirical
longitudinal data on the uptake of drugs, such as sales statistics.
However, in most cases, these were only available for recent years
when the drugs were already registered for some years. Thus, sales
statistics were mainly used to verify that the drug had diffused.
Instead, diffusion was often considered to have begun with the first
clinical trials in each country, provided indicators of a continued
diffusion were available. For tamoxifen and antiretroviral drugs,
clinical trials started when the drugs was already registered. In
these cases, there may also have been less well documented use of
the drug in some countries not captured by the search for clinical
trials so the variation between countries should therefore be inter-
preted with caution.
There were several indications of a continued diffusion of the
different innovations.
For several innovations, the length of period of diffusion seems
to be similar among the countries according to sales statistics.
This was the case for treatment with cimetidine, oxalaplatin and
cyclosporine. For these pharmaceuticals, variations in use may
instead reflect variation in the start of the diffusion among the
countries.
In most cases ,there was a time lag of between 7 and 17 years
from the introduction until guidelines were published. Thus, the
presence of clinical guidelines would not reflect an early phase of
the diffusion of innovation promoted by innovators and early adap-
tors. A previous review have found that the mean compliance
rate for guidelines was 54% 3 years after the publication. Thus, it
seems as if the publication of guidelines may reflect the phase
when the innovation diffuses from the early majority to the late
majority.
This would be in line with the theory of diffusion of innovation,
where the late majority is considered to be more conservative and
will not adopt an innovation until it is standard practice [11].
Several modifiable reasons have been found for not using proven
pharmaceutical interventions, including clinician, patient and
system factors [83]. Thus, it may be possible to influence the
implementation of a pharmaceutical innovation in order to limit
the variation in introduction and diffusion.
Implications for evaluation of medical care
In order to establish a new medical drug in medical practice, its
efficacy must be proved in clinical trials and the drug must be
approved by the regulatory authorities based on data on efficacy
and safety. Efficacy refers to the potential of improving health of
the patients under ideal conditions [84] of use, which should be the
case in clinical trials. The pharmaceuticals studied in this paper
have all passed this phase of assessment and have been approved
for use in medical practice.
However, we must also consider that the effectiveness, defined
as what is achieved under ordinary conditions, may vary [84].
There may be variation in the uptake of pharmaceuticals and other
medical interventions and the quality of care may differ. Thus, the
outcome of medical care may differ from what would be expected
from the results of clinical trials. As pointed out by Brook and
Lohr [84], there is need to integrate the concepts of efficacy,
effectiveness, variations in population-based rates of use and
quality of care when building models for policy, planning and
evaluation of medical care.
In order to assess the impact on populations health of a new
medical drug, we have to be able to measure the timing of intro-
duction of the new drug as well as the diffusion process [11]. This
information should then be linked to population outcome meas-
ures, in order to assess whether the new treatment has been effec-
tive in improving the health of the population [27].
Although the introduction of a new drug may be regarded as
the date of registration, this paper has shown that the year when
the drug was first used in medical care often differs from the
official registration year. According to the theory of diffusion of
innovations [11], the medical intervention may be introduced by
innovators but in order to have a broader impact on populations
health, there must also be a continued diffusion of the innova-
tion. When applying this concept, we found that the registration
year of the pharmaceuticals studied may differ from the year
of introduction with a range between 11 years before and after
the registration year. In assessing any impact on population
health, therefore, the key issue is when the drug came into wide-
spread use.
However, although we used a wide range of data in order to
ascertain the introduction and diffusion of new innovations, our
main finding is the need for harmonized data in EU countries. The
lack of data on different phases of the diffusion process limited the
possibilities to analyse the impact of introduction and diffusion of
the new drugs.
Data on the diffusion of drugs and not simply the registration
year should routinely be documented in a comparable way across
the EU. This is most likely going to require prescribing data, which
at present is inconsistent and only some elements are in the public
domain. This should, ideally, include information on the indica-
tions for prescribing, although clearly, this will not be possible for
some time, except where functioning patient information systems
at a population level exist. It will also be important to use harmo-
nized measures of the amount of drugs prescribed, such as the
DDD [42]. Such improvements in the information on the introduc-
tion and diffusion of drugs would be a valuable tool in evaluating
and planning health care.
Conclusions
Several pharmaceuticals first available in the 1970s and 1980s
were introduced fairly simultaneously in most countries with the
exception for Soviet era Estonia, in which the introduction was
delayed until the 1990s. The delay in introducing the pharmaceu-
ticals was shortest in France, the Netherlands and United
Kingdom. This was true both for year of registration and first
indicators of diffusion of the drugs, suggesting that delays are not
only due to differences in the processes of registration. However,
comparisons are challenging and there is a need for improved
information on the introduction and diffusion of therapeutic inno-
vations to inform comparisons of health system performance.
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